Assembly Bio, Arbutus Bio commence trial of triple combo therapy in hepatitis B
Feb. 26, 2021 7:52 AM ETAssembly Biosciences, Inc. (ASMB)By: Mamta Mayani, SA News Editor
Assembly Biosciences (NASDAQ:ASMB) and Arbutus Biopharma (NASDAQ:ABUS) have initiated a Phase 2 clinical trial of Assembly Bio’s investigational capsid inhibitor, vebicorvir (VBR), in combination with Arbutus’ GalNAc delivered RNAi therapeutic candidate, AB-729, and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for the treatment of chronic HBV infection.
The Phase 2 trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triple combination of VBR, AB-729 and an NrtI compared to the double combinations of VBR with an NrtI and AB-729 with an NrtI.
Approx. 60 patients with HBeAg negative chronic HBV are expected to be enrolled across these three treatment arms.
The primary objective is to evaluate the safety and tolerability of the triple combination, while secondary objectives include to evaluate reduction in HBV viral biomarkers such as HBV DNA, HBV pgRNA and HBsAg.
The companies initially collaborated in August 2020.
ASMB is down 5% whereas ABUS gains 4.7% premarket. 作者: StephenW 时间: 2021-2-27 10:23
